Related Experiment Video
Updated: Jul 19, 2025

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
Molecular characteristics of gastric cancer with ERBB2 amplification
Dongyan Cao1,2, Hongping Xu2, Longteng Li2
1Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
Abstract:
Gastric cancer is a prevalent malignancy with a high degree of heterogeneity, which has led to a poor therapeutic response. Though there are numerous HER2-targeted medicines for HER2+ gastric cancer, many trials have not indicated an improvement in overall survival. Here 29 ERBB2 amplification (ERBB2-Amp) type gastric cancer samples with WES and RNA-seq data were selected for investigation, which copy-number aberration (CNA) was +2. Initially, the somatic mutation and copy number variant (CNV) of them, which might cause resistance to HER2-targeted therapies, were systematically investigated evaluated, as well as their mutation signatures. Moreover, 37 modules were identified using weighted gene co-expression network analysis (WGCNA), including the blue module related to DFS status and lightcyan module correlated with ARHGAP26_ARHGAP6_CLDN18 rearrangement. In addition, focal adhesion and ECM-receptor interaction pathways were considerably enriched in the turquoise module with ERBB2 gene. ExportNetworkToCytoscape determined that MIEN1 and GRB7 are tightly connected to ERBB2., Finally, 14 single-cell intestinal gastric cancer samples were investigated, and it was shown that the TFAP2A transcription factor regulon was highly expressed in ERBB2high group, as was the EMT score. Overall, our data provide comprehensive molecular characteristics of ERBB2-Amp type gastric cancer, which offers additional information to improve HER2-targeted gastric cancer treatment.
Insights
This study investigated ERBB2-amplified gastric cancer, revealing molecular features that may drive resistance to HER2-targeted therapies. Understanding these characteristics can help improve treatment strategies for this aggressive cancer.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Gastric cancer is a heterogeneous malignancy with poor therapeutic outcomes.
- HER2-targeted therapies for HER2-positive gastric cancer often fail to improve overall survival.
Purpose of the Study:
- To investigate the molecular characteristics of ERBB2-amplified gastric cancer.
- To identify potential mechanisms of resistance to HER2-targeted therapies.
Main Methods:
- Whole exome sequencing (WES) and RNA-sequencing on 29 ERBB2-amplified gastric cancer samples.
- Weighted gene co-expression network analysis (WGCNA) to identify gene modules.
- Single-cell analysis of 14 intestinal gastric cancer samples.
Main Results:
- Somatic mutations, copy number variants, and mutation signatures associated with HER2-targeted therapy resistance were evaluated.
- WGCNA identified modules linked to disease-free survival (DFS) and specific gene rearrangements.
- Enrichment of focal adhesion and ECM-receptor interaction pathways in the ERBB2 gene module.
- MIEN1 and GRB7 were identified as tightly connected to ERBB2.
- High expression of TFAP2A transcription factor regulon and EMT score in ERBB2high gastric cancer.
Conclusions:
- Comprehensive molecular profiles of ERBB2-amplified gastric cancer were elucidated.
- Identified molecular features provide insights into treatment resistance.
- Findings offer potential avenues for improving HER2-targeted gastric cancer therapy.
Related Concept Videos
Mitogens and the Cell Cycle
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Barrett Esophagus-I: Introduction
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...

